Related Experiment Videos
Biowaiver monographs for immediate release solid oral dosage forms: ranitidine hydrochloride
H Kortejärvi1, M Yliperttula, J B Dressman
1Orion Pharma, Research and Development, Espoo, Finland.
Journal of Pharmaceutical Sciences
|June 17, 2005
Summary
A biowaiver for ranitidine hydrochloride immediate-release solid oral dosage forms is recommended. This applies to rapidly dissolving formulations with specific excipients, despite its BCS Class III classification.
Area of Science:
- Pharmaceutical Sciences
- Drug Development
- Regulatory Science
Background:
- Ranitidine hydrochloride is typically classified as Biopharmaceutics Classification System (BCS) Class III.
- Regulatory approval often requires in vivo bioequivalence testing for drug products.
Purpose of the Study:
- To review literature and experimental data supporting a waiver of in vivo bioequivalence testing for ranitidine hydrochloride immediate-release (IR) solid oral dosage forms.
- To evaluate the suitability of ranitidine hydrochloride for biowaiver based on its properties and excipient interactions.
Main Methods:
- Review of existing literature on ranitidine hydrochloride's pharmacokinetic properties.
- Analysis of experimental data concerning potential excipient interactions.
- Assessment of ranitidine hydrochloride's therapeutic index and therapeutic properties.
Main Results:
- Ranitidine hydrochloride exhibits properties that support its potential for a biowaiver.
- Rapidly dissolving IR solid oral dosage forms with specific excipients may not require in vivo bioequivalence testing.
- Excipient compatibility data is crucial for supporting biowaiver applications.
Conclusions:
- A biowaiver is justifiable for specific ranitidine hydrochloride IR solid oral dosage forms.
- Formulations must be rapidly dissolving and utilize well-characterized, compatible excipients.
- This approach can streamline the regulatory approval process for certain ranitidine hydrochloride products.